688062 迈威生物
交易中 04-15 10:08:34
资讯
新帖
简况
迈威生物“A+H”双平台启航：ADC尖刀出鞘，平台优势铸就底色
格隆汇 · 45分钟前
迈威生物“A+H”双平台启航：ADC尖刀出鞘，平台优势铸就底色
迈威生物孵化企业Synusight研发的α-突触核蛋白PET示踪剂SST001获国家药监局临床试验批准
美股速递 · 08:00
迈威生物孵化企业Synusight研发的α-突触核蛋白PET示踪剂SST001获国家药监局临床试验批准
迈威生物（688062）披露董事会审议通过H股全球发售及港交所上市议案，4月7日股价下跌1.15%
证券之星 · 04-07
迈威生物（688062）披露董事会审议通过H股全球发售及港交所上市议案，4月7日股价下跌1.15%
每周股票复盘：迈威生物（688062）H股上市聆讯已完成
证券之星 · 04-05
每周股票复盘：迈威生物（688062）H股上市聆讯已完成
迈威生物通过港交所聆讯 两年累计亏损超20亿元
智通财经 · 04-03
迈威生物通过港交所聆讯 两年累计亏损超20亿元
【机构调研记录】银华基金调研迈威生物
证券之星 · 04-02
【机构调研记录】银华基金调研迈威生物
【机构调研记录】同泰基金调研广电计量、迈威生物等4只个股（附名单）
证券之星 · 04-02
【机构调研记录】同泰基金调研广电计量、迈威生物等4只个股（附名单）
每周股票复盘：迈威生物（688062）2025年营收增231.62%
证券之星 · 03-29
每周股票复盘：迈威生物（688062）2025年营收增231.62%
迈威生物、剂泰科技、星环科技递表港交所；特步国际、康臣药业、快手公布2025年年度业绩丨港交所早参
每日经济新闻 · 03-27
迈威生物、剂泰科技、星环科技递表港交所；特步国际、康臣药业、快手公布2025年年度业绩丨港交所早参
新股消息 | 迈威生物(688062.SH)二次递表港交所
智通财经 · 03-25
新股消息 | 迈威生物(688062.SH)二次递表港交所
迈威生物(688062.SH)发布2025年度业绩，归母净亏损9.69亿
智通财经 · 03-24
迈威生物(688062.SH)发布2025年度业绩，归母净亏损9.69亿
3月3日迈威生物跌5.58%，易方达医疗保健行业混合A基金重仓该股
证券之星 · 03-03
3月3日迈威生物跌5.58%，易方达医疗保健行业混合A基金重仓该股
新股消息 | 迈威生物(688062.SH)港股IPO招股书失效
智通财经 · 03-02
新股消息 | 迈威生物(688062.SH)港股IPO招股书失效
股市必读：迈威生物发布2025年度业绩快报，亏损9.702亿元
证券之星 · 03-02
股市必读：迈威生物发布2025年度业绩快报，亏损9.702亿元
每周股票复盘：迈威生物（688062）2025年净亏9.7亿同比收窄
证券之星 · 03-01
每周股票复盘：迈威生物（688062）2025年净亏9.7亿同比收窄
迈威生物（688062）披露2025年度业绩快报公告，2月27日股价上涨0.37%
证券之星 · 02-27
迈威生物（688062）披露2025年度业绩快报公告，2月27日股价上涨0.37%
迈威生物（688062）披露关于调整部分募投项目内部投资结构的议案，2月24日股价下跌3.27%
证券之星 · 02-24
迈威生物（688062）披露关于调整部分募投项目内部投资结构的议案，2月24日股价下跌3.27%
每周股票复盘：迈威生物（688062）股东会通过募投项目调整议案
中金财经 · 02-15
每周股票复盘：迈威生物（688062）股东会通过募投项目调整议案
2月2日迈威生物创60日新低，易方达医疗保健行业混合A基金重仓该股
证券之星 · 02-02
2月2日迈威生物创60日新低，易方达医疗保健行业混合A基金重仓该股
迈威生物（688062）披露关于调整部分募投项目内部投资结构的议案，1月28日股价下跌1.95%
证券之星 · 01-28
迈威生物（688062）披露关于调整部分募投项目内部投资结构的议案，1月28日股价下跌1.95%
加载更多
公司概况
公司名称：
迈威(上海)生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2022-01-18
主营业务：
迈威(上海)生物科技股份有限公司的主营业务是研发、生产以及销售创新型药物和生物类似药。公司的主要产品是抗体、ADC药物和重组蛋白、小分子化学药等药物。
发行价格：
34.80
{"stockData":{"symbol":"688062","market":"SH","secType":"STK","nameCN":"迈威生物","latestPrice":38.36,"timestamp":1776218914000,"preClose":38.45,"halted":0,"volume":6046282,"delay":0,"changeRate":-0.0023,"floatShares":204000000,"shares":400000000,"eps":-2.2392,"marketStatus":"交易中","change":-0.09,"latestTime":"04-15 10:08:34","open":39.34,"high":40.47,"low":38.04,"amount":235000000,"amplitude":0.0632,"askPrice":38.36,"askSize":5,"bidPrice":38.35,"bidSize":60,"shortable":0,"etf":0,"ttmEps":-2.2392,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1776223800000},"marketStatusCode":2,"adr":0,"adjPreClose":38.45,"symbolType":"stock_kcb","openAndCloseTimeList":[[1776216600000,1776223800000],[1776229200000,1776236400000]],"highLimit":42.3,"lowLimit":34.61,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":399600000,"isCdr":false,"pbRate":43.96,"roa":"--","roe":"--","epsLYR":-2.43,"committee":0.440559,"marketValue":15329000000,"turnoverRate":0.0296,"status":1,"floatMarketCap":7832000000},"requestUrl":"/m/hq/s/688062","defaultTab":"news","newsList":[{"id":"2627747642","title":"迈威生物“A+H”双平台启航：ADC尖刀出鞘，平台优势铸就底色","url":"https://stock-news.laohu8.com/highlight/detail?id=2627747642","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627747642?lang=zh_cn&edition=full","pubTime":"2026-04-15 09:24","pubTimestamp":1776216266,"startTime":"0","endTime":"0","summary":"随着核心品种关键临床节点密集兑现、全球化布局稳步落地，这家年轻的中国创新药企，正以ADC为利刃，借政策与资本东风，在全球肿瘤创新药赛场，奏响中国药企突围进阶的时代强音。","market":"sh","thumbnail":"https://img2.gelonghui.com/b9ad4-4ef65188-5c75-45f1-aeaa-9221d6b4720f.jpg?guru_height=852&guru_width=1280&guru_size=143965","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/b9ad4-4ef65188-5c75-45f1-aeaa-9221d6b4720f.jpg?guru_height=852&guru_width=1280&guru_size=143965"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4411775","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK4231","BK4080","ADC","BK0239","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152771691","title":"迈威生物孵化企业Synusight研发的α-突触核蛋白PET示踪剂SST001获国家药监局临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1152771691","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152771691?lang=zh_cn&edition=full","pubTime":"2026-04-15 08:00","pubTimestamp":1776211216,"startTime":"0","endTime":"0","summary":"由迈威生物孵化企业Synusight Biotech研发的α-突触核蛋白PET示踪剂SST001，近日正式获得国家药品监督管理局批准开展临床试验。该突破性进展标志着神经退行性疾病诊断领域迎来重要技术突破。作为靶向病理性α-突触核蛋白的特异性分子影像探针，SST001有望为帕金森病、路易体痴呆等疾病的早期精准诊断提供全新解决方案。随着临床试验的推进，该产品有望填补国内α-突触核蛋白PET影像诊断市场空白。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688062","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625959349","title":"迈威生物（688062）披露董事会审议通过H股全球发售及港交所上市议案，4月7日股价下跌1.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625959349","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625959349?lang=zh_cn&edition=full","pubTime":"2026-04-07 22:12","pubTimestamp":1775571143,"startTime":"0","endTime":"0","summary":"截至2026年4月7日收盘，迈威生物报收于37.72元，较前一交易日下跌1.15%，最新总市值为150.73亿元。该股当日开盘38.0元，最高38.67元，最低36.52元，成交额达3.4亿元，换手率为4.43%。近日，迈威（上海）生物科技股份有限公司发布《第二届董事会第三十次会议决议公告》。会议还审议通过了豁免本次董事会通知期限的议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700033383.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688062","HEXmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625615053","title":"每周股票复盘：迈威生物（688062）H股上市聆讯已完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2625615053","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625615053?lang=zh_cn&edition=full","pubTime":"2026-04-05 01:34","pubTimestamp":1775324051,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，迈威生物报收于38.16元，较上周的36.32元上涨5.07%。本周关注点来自公司公告汇总：迈威生物H股发行聆讯后资料集已刊发，上市进程取得重要进展。公司公告汇总国泰海通证券股份有限公司对迈威生物2025年度持续督导情况进行报告。国泰海通证券股份有限公司出具关于迈威（上海）生物科技股份有限公司首次公开发行股票并上市的保荐总结报告书。2025年11月19日，公司获得中国证监会境外发行上市备案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000227.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624844636","title":"迈威生物通过港交所聆讯 两年累计亏损超20亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2624844636","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624844636?lang=zh_cn&edition=full","pubTime":"2026-04-03 08:36","pubTimestamp":1775176560,"startTime":"0","endTime":"0","summary":"据港交所4月2日披露，迈威(上海)生物科技股份有限公司(迈威生物(688062.SH))通过港交所主板上市聆讯，中信证券和海通国际为联席保荐人。招股书显示，迈威生物是一家中国制药公司，主要专注 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20260403/c675742728.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688062","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624281725","title":"【机构调研记录】银华基金调研迈威生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2624281725","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624281725?lang=zh_cn&edition=full","pubTime":"2026-04-02 08:12","pubTimestamp":1775088773,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及4月1日披露的机构调研信息，银华基金近期对1家上市公司进行了调研，相关名单如下：1）迈威生物 调研纪要：TCE领域热度高但未形成绝对头部，公司将打造和完善技术平台，推出差异化管线。银华基金成立于2001年，截至目前，资产管理规模6515.52亿元，排名22/212；资产管理规模3173.99亿元，排名20/212；管理公募基金数407只，排名18/212；旗下公募基金经理78人，排名12/212。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200005283.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624289025","title":"【机构调研记录】同泰基金调研广电计量、迈威生物等4只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2624289025","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624289025?lang=zh_cn&edition=full","pubTime":"2026-04-02 08:12","pubTimestamp":1775088736,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及4月1日披露的机构调研信息，同泰基金近期对4家上市公司进行了调研，相关名单如下：1）广电计量 调研纪要：2025年，公司加快向商业航天、低空经济、人工智能等高成长赛道转型，高毛利业务带动净利率提升。同泰基金成立于2018年，截至目前，资产管理规模35.72亿元，排名163/212；资产管理规模35.66亿元，排名140/212；管理公募基金数48只，排名109/212；旗下公募基金经理6人，排名132/212。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200005232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002967","688062","BK0221"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623387094","title":"每周股票复盘：迈威生物（688062）2025年营收增231.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623387094","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623387094?lang=zh_cn&edition=full","pubTime":"2026-03-29 01:44","pubTimestamp":1774719851,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，迈威生物报收于36.32元，较上周的33.02元上涨9.99%。本周，迈威生物3月27日盘中最高价报36.89元。本周关注点来自业绩披露要点：迈威生物2025年主营收入6.63亿元，同比上升231.62%。股本股东变化截至2026年2月28日，迈威生物股东户数为1.86万户，较2024年末增加254户，增幅1.39%。公司公告汇总迈威生物于2026年3月20日完成2026年度第一期定向科技创新债券发行，实际发行总额8,500万元，利率2.9%，募集资金用于偿还有息债务及临床研发支出。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032900000240.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622893988","title":"迈威生物、剂泰科技、星环科技递表港交所；特步国际、康臣药业、快手公布2025年年度业绩丨港交所早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2622893988","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622893988?lang=zh_cn&edition=full","pubTime":"2026-03-27 02:31","pubTimestamp":1774549863,"startTime":"0","endTime":"0","summary":"NO.1迈威生物、剂泰科技、星环科技递表港交所据港交所3月25日消息，迈威（上海）生物科技股份有限公司-B（以下简称迈威生物，SH688062）、剂泰科技（北京）股份有限公司-P（以下简称剂泰科技）、星环信息科技（上海）股份有限公司（以下简称星环科技，SH688031）已向港交所递交上市申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603273686067484.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603273686067484.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1591","LU0593848301.USD","BK1606","LU2097828714.EUR","BK1590","LU0456827905.SGD","LU0702159343.USD","LU1794554557.SGD","BK1583","LU0140636845.USD","LU0463099449.HKD","LU2097828805.USD","LU1719994722.HKD","LU0210526637.USD","KSTmain","LU0051755006.USD","LU0348766576.USD","BK1502","LU0702159699.USD","LU1023057109.AUD","LU0359201612.USD","LU0326950275.SGD","LU2097828557.USD","BK1608","LU0588546209.SGD","LU1166156734.SGD","LU2097828474.EUR","LU1303224171.USD","LU0244354667.USD","LU0572944931.SGD","LU0211977185.USD","LU1770034418.SGD","81024","01681","LU0327786744.USD","XTEPY","BK1512","BK1095","688062","BK0239","01024","BK1168","LU1188198961.HKD","LU2097828631.EUR","BK1610","BK1575","BK1191","01368","LU0359201885.HKD","LU0359202008.SGD","LU1251922891.USD","BK0231","BK1615","LU1720050803.USD","LU0348767384.USD","LU0307460666.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2622071230","title":"新股消息 | 迈威生物(688062.SH)二次递表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2622071230","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622071230?lang=zh_cn&edition=full","pubTime":"2026-03-25 21:45","pubTimestamp":1774446320,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所3月25日披露，迈威(上海)生物科技股份有限公司(迈威生物(688062.SH))向港交所主板递交上市申请书，中信证券和海通国际为联席保荐人。这是该公司第二次递表港交所。据招股书，迈威生物的核心产品9MW2821是一款靶向Nectin细胞黏附分子4的抗体偶联药物。此外，公司已建立包括13个以上不同品种的药物资产的管线产品组合。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419046.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","HEXmain","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621060571","title":"迈威生物(688062.SH)发布2025年度业绩，归母净亏损9.69亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2621060571","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621060571?lang=zh_cn&edition=full","pubTime":"2026-03-24 21:13","pubTimestamp":1774358034,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物 发布2025年年度报告，报告期内，公司实现营业收入6.63亿元，同比增长231.62%。归属于上市公司股东的净亏损9.69亿元，归属于上市公司股东的扣除非经常性损益的净亏损9.99亿元，基本每股亏损2.43元。报告期归属于上市公司股东的净亏损较上年同期减少7,458.56万元，归属于上市公司股东的扣除非经常性损益的净亏损较上年同期减少7,075.02万元，主要系公司与齐鲁制药、DISC的授权许可合同确认收入金额较大，同时药品销售收入增加较多。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418280.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"迈威生物(688062.SH)发布2025年度业绩，归母净亏损9.69亿","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688062","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616312410","title":"3月3日迈威生物跌5.58%，易方达医疗保健行业混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2616312410","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616312410?lang=zh_cn&edition=full","pubTime":"2026-03-03 16:33","pubTimestamp":1772526805,"startTime":"0","endTime":"0","summary":"证券之星消息，3月3日迈威生物跌5.58%创60日新低，收盘报31.65元，换手率3.97%，成交量8.11万手，成交额2.62亿元。重仓迈威生物的前十大公募基金请见下表：该股最近90天内共有4家机构给出评级，买入评级4家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共26家，其中持有数量最多的公募基金为易方达基金的易方达医疗保健行业混合A。易方达医疗保健行业混合A目前规模为30.94亿元，最新净值3.698，较上一交易日下跌2.66%，近一年上涨14.95%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030300028938.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616013478","title":"新股消息 | 迈威生物(688062.SH)港股IPO招股书失效","url":"https://stock-news.laohu8.com/highlight/detail?id=2616013478","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616013478?lang=zh_cn&edition=full","pubTime":"2026-03-02 11:43","pubTimestamp":1772423014,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，迈威(上海)生物科技股份有限公司(迈威生物)(688062.SH)于2025年8月29日所递交的港股招股书满6个月，于近日失效。据招股书，迈威生物是一家主要专注于自主开发肿瘤和年龄相关疾病药物并处于商业化阶段的制药公司。多年来，公司建立了具有竞争力的、多层次的管线产品组合，包括10个以上的药物资产且覆盖不同品种，专注于肿瘤和年龄相关疾病，如免疫、眼科、骨科等领域。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408852.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VT","BK4585","688062","VXUS","BK0239","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616875172","title":"股市必读：迈威生物发布2025年度业绩快报，亏损9.702亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616875172","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616875172?lang=zh_cn&edition=full","pubTime":"2026-03-02 02:14","pubTimestamp":1772388853,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，迈威生物报收于34.93元，上涨0.37%，换手率1.72%，成交量3.51万手，成交额1.23亿元。来自业绩披露要点：迈威生物预计2025年归属净利润亏损9.702亿元，同比收窄7.06%。公司公告汇总迈威生物2025年度业绩快报公告迈威生物发布2025年度业绩快报，营业总收入66,251.56万元，同比增长231.62%。归属于母公司所有者权益同比下降77.78%，主要因研发投入高、商业化拓展致成本费用上升。加权平均净资产收益率下降48.77个百分点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200001016.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616431078","title":"每周股票复盘：迈威生物（688062）2025年净亏9.7亿同比收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2616431078","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616431078?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:13","pubTimestamp":1772302390,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，迈威生物报收于34.93元，较上周的36.42元下跌4.09%。本周，迈威生物2月24日盘中最高价报36.7元。迈威生物当前最新总市值139.58亿元，在化学制药板块市值排名39/150，在两市A股市值排名1566/5189。本周关注点来自业绩披露要点：迈威生物2025年归属净利润亏损9.702亿元，同比收窄7.06%。公司公告汇总迈威生物发布2025年度业绩快报，营业总收入66,251.56万元，同比增长231.62%，主要由于与齐鲁制药、DISC MEDICINE, INC.的授权许可合同确认收入较大，以及药品销售收入增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000710.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614524228","title":"迈威生物（688062）披露2025年度业绩快报公告，2月27日股价上涨0.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614524228","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614524228?lang=zh_cn&edition=full","pubTime":"2026-02-27 22:50","pubTimestamp":1772203823,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，迈威生物报收于34.93元，较前一交易日上涨0.37%，最新总市值为139.58亿元。该股当日开盘34.78元，最高35.25元，最低34.51元，成交额达1.23亿元，换手率为1.72%。公告显示，公司2025年营业总收入为66,251.56万元，同比增长231.62%。营业利润为-95,615.95万元，归属于母公司所有者的净利润为-97,017.55万元。归属于母公司所有者权益同比下降77.78%，主要因研发投入高、商业化拓展致成本费用上升。加权平均净资产收益率下降48.77个百分点。上述数据为初步核算结果，未经审计。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700042759.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613079166","title":"迈威生物（688062）披露关于调整部分募投项目内部投资结构的议案，2月24日股价下跌3.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613079166","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613079166?lang=zh_cn&edition=full","pubTime":"2026-02-24 17:32","pubTimestamp":1771925574,"startTime":"0","endTime":"0","summary":"截至2026年2月24日收盘，迈威生物报收于35.23元，较前一交易日下跌3.27%，最新总市值为140.78亿元。该股当日开盘36.7元，最高36.7元，最低35.0元，成交额达2.02亿元，换手率为2.78%。公告显示，公司于2026年2月13日召开2026年第一次临时股东会，审议通过《关于公司调整部分募投项目内部投资结构的议案》。出席会议的股东共129人，代表有表决权股份总数205,575,336股，占公司总表决权数的51.4452%。该议案对中小投资者单独计票，表决程序符合相关规定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400033205.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611614497","title":"每周股票复盘：迈威生物（688062）股东会通过募投项目调整议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2611614497","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611614497?lang=zh_cn&edition=full","pubTime":"2026-02-15 08:05","pubTimestamp":1771113913,"startTime":"0","endTime":"0","summary":"本周，迈威生物2月10日盘中最高价报37.89元。迈威生物当前最新总市值145.53亿元，在化学制药板块市值排名36/150，在两市A股市值排名1456/5189。出席会议的股东共129人，代表有表决权股份总数205,575,336股，占公司总表决权数的51.4452%。北京植德(上海)律师事务所对本次会议出具法律意见，确认会议召集、召开程序及表决结果合法有效。会议审议通过《关于公司调整部分募投项目内部投资结构的议案》，无关联股东需回避表决。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260215/32019328.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688062","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608851807","title":"2月2日迈威生物创60日新低，易方达医疗保健行业混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2608851807","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608851807?lang=zh_cn&edition=full","pubTime":"2026-02-02 16:40","pubTimestamp":1770021648,"startTime":"0","endTime":"0","summary":"证券之星消息，2月2日迈威生物创60日新低，收盘报34.78元，当日跌3.42%，换手率3.14%，成交量6.41万手，成交额2.27亿元。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共26家，其中持有数量最多的公募基金为易方达基金的易方达医疗保健行业混合A。易方达医疗保健行业混合A目前规模为30.94亿元，最新净值3.96，较上一交易日下跌0.13%，近一年上涨33.15%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200023398.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606717868","title":"迈威生物（688062）披露关于调整部分募投项目内部投资结构的议案，1月28日股价下跌1.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606717868","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606717868?lang=zh_cn&edition=full","pubTime":"2026-01-28 22:14","pubTimestamp":1769609661,"startTime":"0","endTime":"0","summary":"截至2026年1月28日收盘，迈威生物报收于37.75元，较前一交易日下跌1.95%，最新总市值为150.85亿元。近日，迈威（上海）生物科技股份有限公司发布《2026年第一次临时股东会会议资料》公告，拟对2022年首次公开发行股份募投项目中的“抗体药物研发项目”内部投资结构进行调整，减少9MW0311、9MW0321、8MW0511、9MW1111、9MW1411、6MW3211项目的募集资金投入合计9,083.18万元，并将该部分资金用于增加9MW2821项目的投入。本次调整不涉及募投项目计划投入募集资金总额的变更。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800042648.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1776218918179,"stockEarnings":[{"period":"1week","weight":0.0194},{"period":"1month","weight":0.1613},{"period":"3month","weight":-0.0974},{"period":"6month","weight":-0.1768},{"period":"1year","weight":0.7509},{"period":"ytd","weight":-0.0005}],"compareEarnings":[{"period":"1week","weight":0.0351},{"period":"1month","weight":-0.0168},{"period":"3month","weight":-0.0241},{"period":"6month","weight":0.0282},{"period":"1year","weight":0.2341},{"period":"ytd","weight":0.0146}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"迈威(上海)生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"18567人(较上一季度增加1.39%)","perCapita":"10996股","listingDate":"2022-01-18","address":"上海市浦东新区中国(上海)自由贸易试验区蔡伦路230号2幢105室","registeredCapital":"39960万元","survey":" 迈威(上海)生物科技股份有限公司的主营业务是研发、生产以及销售创新型药物和生物类似药。公司的主要产品是抗体、ADC药物和重组蛋白、小分子化学药等药物。","listedPrice":34.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迈威生物(688062)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迈威生物(688062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迈威生物,688062,迈威生物股票,迈威生物股票老虎,迈威生物股票老虎国际,迈威生物行情,迈威生物股票行情,迈威生物股价,迈威生物股市,迈威生物股票价格,迈威生物股票交易,迈威生物股票购买,迈威生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迈威生物(688062)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迈威生物(688062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}